235 related articles for article (PubMed ID: 16551740)
21. Association between a 11β-hydroxysteroid dehydrogenase type 1 gene polymorphism and metabolic syndrome in a South Indian population.
Gandhi K; Adhikari P; Basu A; Achappa B
Metab Syndr Relat Disord; 2013 Dec; 11(6):397-402. PubMed ID: 23869418
[TBL] [Abstract][Full Text] [Related]
22. The upregulation of 11β-HSD1 in ovarian granulosa cells by cortisol and interleukin-1β in polycystic ovary syndrome.
Wu H; Zhu Q; Li X; He Y; Wang Y; Lu Y; Qi J; Ding Y; Li J; Xu R; Sun Y
Gynecol Endocrinol; 2020 Aug; 36(8):668-672. PubMed ID: 31902257
[TBL] [Abstract][Full Text] [Related]
23. Local Regeneration of Cortisol by 11β-HSD1 Contributes to Insulin Resistance of the Granulosa Cells in PCOS.
Zhu Q; Zuo R; He Y; Wang Y; Chen ZJ; Sun Y; Sun K
J Clin Endocrinol Metab; 2016 May; 101(5):2168-77. PubMed ID: 26934392
[TBL] [Abstract][Full Text] [Related]
24. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
25. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
26. Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS).
Marioli DJ; Saltamavros AD; Vervita V; Koika V; Adonakis G; Decavalas G; Markou KB; Georgopoulos NA
Fertil Steril; 2009 Aug; 92(2):648-52. PubMed ID: 18692800
[TBL] [Abstract][Full Text] [Related]
27. Association of genetic variants in the two isoforms of 5α-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
Graupp M; Wehr E; Schweighofer N; Pieber TR; Obermayer-Pietsch B
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):175-9. PubMed ID: 21530059
[TBL] [Abstract][Full Text] [Related]
28. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism.
Peral B; San Millán JL; Castello R; Moghetti P; Escobar-Morreale HF
J Clin Endocrinol Metab; 2002 Aug; 87(8):3977-83. PubMed ID: 12161545
[TBL] [Abstract][Full Text] [Related]
29. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
Walker BR; Rodin A; Taylor NF; Clayton RN
Clin Endocrinol (Oxf); 2000 Jan; 52(1):77-80. PubMed ID: 10651756
[TBL] [Abstract][Full Text] [Related]
30. Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample.
White PC
J Clin Endocrinol Metab; 2005 Oct; 90(10):5880-3. PubMed ID: 16091483
[TBL] [Abstract][Full Text] [Related]
31. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess.
Witchel SF; Kahsar-Miller M; Aston CE; White C; Azziz R
Fertil Steril; 2005 Feb; 83(2):371-5. PubMed ID: 15705377
[TBL] [Abstract][Full Text] [Related]
33. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
[TBL] [Abstract][Full Text] [Related]
34. A genetic risk score is associated with polycystic ovary syndrome-related traits.
Lee H; Oh JY; Sung YA; Chung HW
Hum Reprod; 2016 Jan; 31(1):209-15. PubMed ID: 26573528
[TBL] [Abstract][Full Text] [Related]
35. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
36. Tissue-specific dysregulation of cortisol metabolism in human obesity.
Rask E; Olsson T; Söderberg S; Andrew R; Livingstone DE; Johnson O; Walker BR
J Clin Endocrinol Metab; 2001 Mar; 86(3):1418-21. PubMed ID: 11238541
[TBL] [Abstract][Full Text] [Related]
37. Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype.
Louwers YV; de Jong FH; van Herwaarden NA; Stolk L; Fauser BC; Uitterlinden AG; Laven JS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3848-55. PubMed ID: 23861462
[TBL] [Abstract][Full Text] [Related]
38. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
39. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
Moran C; Reyna R; Boots LS; Azziz R
Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555
[TBL] [Abstract][Full Text] [Related]
40. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
